438050-33-0Relevant articles and documents
Discovery of HTL6641, a dual orexin receptor antagonist with differentiated pharmacodynamic properties
Christopher, John A.,Aves, Sarah J.,Brown, Jason,Errey, James C.,Klair, Suki S.,Langmead, Christopher J.,Mace, Oliver J.,Mould, Richard,Patel, Jayesh C.,Tehan, Benjamin G.,Zhukov, Andrei,Marshall, Fiona H.,Congreve, Miles
supporting information, p. 947 - 955 (2015/05/27)
A novel series of potent, selective, and orally efficacious dual antagonists of the orexin receptors has been investigated, resulting in the identification of lead compound 27 (HTL6641). Comprehensive data for 27 are presented, including in vivo PK parame
Novel piperazine derivatives
-
, (2008/06/13)
The present invention is a chemical compound of formula (I) or a pharmaceutically acceptable salts, solvates and esters thereof, wherein R1 to R4, A1, A2 m and n are as described in the specification.